Comprehensive Dermatologic Drug Therapy, 2nd Edition

Comprehensive Dermatologic Drug Therapy

2nd Edition

By Stephen E. Wolverton, MD, Professor of Clinical Dermatology and Vice Chair of Clinical Affairs, Department of Dermatology, Indiana University Medical Center; Chief of Dermatology, Roudebush VA Medical Center, Indianapolis, IN, USA


I. Introduction

1. Basic Principles of Pharmacology (Stephen E. Wolverton)
2. Principles for Maximizing the Safety of Dermatologic Drug Therapy (Stephen E. Wolverton)
3. Polymorphisms: Why Individual Drug Responses Vary (Benjamin N. Lockshin, Stephen E. Wolverton)

II. Systemic Drugs for Infectious Diseases

4. Systemic Antibacterial Agents (Neda Ashourian, Philip R. Cohen)
5. Systemic Antifungal Agents (Aditya K. Gupta )
6. Systemic Antiviral Agents (Y. Connie Chang, Vandana K. Madkan, Karan Sra, Daniel A. Carrasco, Patricia C. Lee, Stephen K. Tyring)

III. Systemic Immunomodulatory and Antiproliferative Drugs

7. Systemic Corticosteriods (Stephen E. Wolverton)
8. Methotrexate (Jeffrey P. Callen, Carol L. Kulp-Shorten, Stephen E. Wolverton)
9. Azathioprine (Stephanie Silos Badalamenti, Francisco A. Kerdel)
10. Cytotoxic Agents (Clifford Perlis, Teddy D. Pan, Charles J. McDonald)
11. Cyclosporine (Chai Sue Lee, John Y.M. Koo)
12.Dapsone (Russell P. Hall III, Clinzo P. Mickle)
13. Antimalarial Agents (Jeffrey P. Callen, Charles Camisa)
14. Systemic Retinoids (Timothy J. Patton, Matthew J. Zirwas, Stephen E. Wolverton)
15. Interferons (Brian Berman, Francisco Flores, Deborah Zel)

IV. Drugs Used in Conjunction with Ultraviolet or Visible Light

16. PUVA Photochemotherapy (Warwick L. Morison)
17. Extracorporeal Photochemotheraphy (Photopheresis) (Michael Girardi, Peter W. Heald)
18. Photodynamic Therapy (Robert Bissonnette, Jaggi Rao)

V. Biological Therapeutics

19. Tumor Necrosis Factor (TNF) Inhibitors (Stephanie Mehlis, Kenneth B. Gordon)
20. T-Cell Activation Inhibitors (Mark G. Lebwohl, Sapna Rao Palep)

VI. Miscellaneous Systemic Drugs

21. Antihistamines (Malcolm W. Greaves)
22. Vasoactive and Antiplatelet Agents (Seth B. Forman, Algin B. Garrett)
23. Antiandrogens and Androgen Inhibitors (Marty E. Sawaya)
24. Psychotropic Agents (Chai Sue Lee, John Y.M. Koo)
25. Intravenous Immunoglobulin Therapy (Kai Thomas, Anita Ruetter, Thomas A. Luger)
26. Miscellaneous Systemic Drugs (Alfred L. Knable Jr., Loretta S. Davis)
27. Drugs for the Skinternist (Michelle Pelle)

VII. Topical Drugs for Infectious Diseases

28. Topical Antibaterial Agents (Deborah J. Yang, Long T. Quan, Sylvia Hsu)
29. Topical Antifungal Agents (Rhea M. Phillips, Theodore Rosen)
30. Topical and Intralesional Antiviral Agents (Pranav B. Sheth)
31. Antiparasitic Agents (Benjamin N. Lockshin)

VIII. Topical Immunomodulatory and Antiproliferative Drugs

32. Topical Corticosteroids (Michael R. Warner, Charles Camisa)
33. Topical Retinoids (Naveed Sami, Julie C. Harper)
34. Topical and Intralesional Chemotherapeutic Agents (Eunice Y. Tsai, Herschel S. Zackheim, Youn H. Kim)
35. Topical Contact Allergens (Andrew N. Lin)
36. Topical Calcineurin Inhibitors (Andrew N. Lin)
37. Topical Vitamin D3 (Yolanda Rosi Helfrich, Dana L. Sachs, Sewon Kang)

IX. Miscellaneous Topical Drugs

38. Sunscreens (Stanley B. Levy)
39. Therapeutic Shampoos (Robert T. Brodell, Kevin D. Cooper)
40. Alpha-Hydroxy Acids (Amy B. Lewis, Helen Radoszycki)
41. Agents Used for Treatment of Hyperkeratosis (Adam B. Hessel, Julio C. Cruz-Ramon, Dana Marshall Klinger, Andrew N. Lin)
42. Cosmetic Therapy (Zoe Diana Draelos)
43. Miscellaneous Topical Agents (Seth B. Forman)
44. Insect Repellents (Mark S. Fradin)
45. Systemic Adverse Effects Due To Topical Medications (Peter J. Aronson)
46. Compounding in Dermatology (Linda F. McElhiney, Scott M. Ravis)

X. Injectable and Mucosal Routes of Drug Administration

47. Local Anesthetics (Michael J. Huether, David G. Brodland)
48. Botulinum Toxin Injections (Christian Murray, Nowell Solish)
49. Oral Mucosal Therapeutics (Ginat Wintermeyer Mirowski, Ernest Lee)

XI. Major Adverse Effects from Systemic Drugs

50. Hepatotoxicity of Dermatologic Drug Therapy (Stephen E. Wolverton)
51. Hematologic Toxicity of Dermatologic Drug Therapy (Kathleen A. Remlinger)
52. Drug Induced Malignancies (Stephen E. Wolverton)
53. Dermatologic Drugs During Pregnancy and Lactation (Barbara R. Reed)
54. Drug Interactions (Lori E. Shapiro, Neil H. Shear)
55. Cutaneous Drug Reactions with Systemic Features (Sandra R. Knowles, Neil H. Shear)

XII. Special Pharmacology and Therapeutic Topics

56. Pharmacoeconomics (Marc Alan Darst, Jennifer Reddan)
57. Informed Consent and Risk Management (Stephen E. Wolverton, Marshall B. Kapp )
58. FDA Drug Approval Process (William H. Eaglstein)
59. Pharmacovigilance: Verifying that Drugs Remain Safe (Joel M. Gelfand)
60. Dermatologic Drug Therapy in Children (Christopher M. Bohyer)

Index

Appendices